U.K. Newborn Screening Market Size & Outlook, 2026-2033
- Clinical Diagnostics
- Genetic Testing
- Newborn Screening Market Outlook
- Genetic Testing
Global Market
Related Markets
Ask a question about the newborn screening market
UK newborn screening market highlights
- The UK newborn screening market generated a revenue of USD 39.2 million in 2025 and is expected to reach USD 71.3 million by 2033.
- The UK market is expected to grow at a CAGR of 7.9% from 2026 to 2033.
- In terms of segment, tandem mass spectrometry was the largest revenue generating technology in 2025.
- Electrophoresis is the most lucrative technology segment registering the fastest growth during the forecast period.
Newborn screening market data book summary
| Market revenue in 2025 | USD 39.2 million |
| Market revenue in 2033 | USD 71.3 million |
| Growth rate | 7.9% (CAGR from 2026 to 2033) |
| Largest segment | Tandem mass spectrometry |
| Fastest growing segment | Electrophoresis |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Tandem Mass Spectrometry, Electrophoresis, Pulse Oximetry, Enzyme-based Assay, DNA Assays |
| Key market players worldwide | Bio-Rad Laboratories Inc, Agilent Technologies, Agilent Technologies Inc, Covidien, Masimo Corp, Waters Corp, Natus Medical, GE HealthCare Technologies Inc Common Stock, PerkinElmer, Danaher Corp |
Other key industry trends
- In terms of revenue, UK accounted for 4.1% of the global newborn screening market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Europe, UK newborn screening market is projected to lead the regional market in terms of revenue in 2033.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 50.8 million by 2033.
The UK National Screening Committee (UK NSC) has been set up to carry out testing over these neonates for evidences of any congenital anomalies. All states of UK uniformly screen for five mandated disorders.
However, Northern Ireland screens for seven anomalies. In May 2014, four new conditions were added that included Isovaleric (IVA), Homocystinuria (HCU), Glutaric Type 1 (GA1), and Maple Syrup Urine Disease (MSUD). Approval for adding these was done post-completion of the pilot study, which was funded by National Institute for Health Research.
No credit card required*
Publish Date: Nov 10, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Newborn Screening Market Scope
Newborn Screening Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GE HealthCare Technologies Inc Common Stock | View profile | 51,000 | 500 West Monroe Street, Chicago, IL, United States, 60661 | www.gehealthcare.com |
| Danaher Corp | View profile | 63,000 | 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701 | www.danaher.com |
| Agilent Technologies Inc | View profile | 17,700 | 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 | www.agilent.com |
| Bio-Rad Laboratories Inc | View profile | 8,030 | 1000 Alfred Nobel Drive, Hercules, CA, United States, 94547 | www.bio-rad.com |
| Waters Corp | View profile | 7,900 | 34 Maple Street, Milford, MA, United States, 01757 | www.waters.com |
| Masimo Corp | View profile | 3,796 | 52 Discovery, Irvine, CA, United States, 92618 | www.masimo.com |
| PerkinElmer | View profile | 10001+ | Waltham, Massachusetts, United States, North America | www.perkinelmer.com |
| Agilent Technologies | View profile | 10001+ | Santa Clara, California, United States, North America | www.agilent.com |
| Natus Medical | View profile | 1001-5000 | San Carlos, California, United States, North America | www.natus.com |
| Covidien | View profile | 10001+ | Dublin, Dublin, Ireland, Europe | www.covidien.com |
U.K. Newborn Screening Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Newborn Screening Market Outlook will help companies and investors design strategic landscapes.
Tandem Mass Spectrometry was the largest segment with a revenue share of 26.79% in 2025.
Horizon Databook has segmented the U.K. newborn screening market based on tandem mass spectrometry, electrophoresis, pulse oximetry, enzyme-based assay, dna assays covering the revenue growth of each sub-segment from 2021 to 2033.
The UK National Screening Committee (UK NSC) has been set up to carry out testing over these neonates for evidences of any congenital anomalies. All states of UK uniformly screen for five mandated disorders.
However, Northern Ireland screens for seven anomalies. In May 2014, four new conditions were added that included Isovaleric (IVA), Homocystinuria (HCU), Glutaric Type 1 (GA1), and Maple Syrup Urine Disease (MSUD). Approval for adding these was done post-completion of the pilot study, which was funded by National Institute for Health Research.
- U.K. Newborn Screening Market Technology Outlook (Revenue, USD Million , 2021-2033)
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme-based Assay
- DNA Assays
- Electrophoresis
- Others
- U.K. Newborn Screening Market Test Type Outlook (Revenue, USD Million , 2021-2033)
- Dry Blood Spot Test
- CCHD
- Hearing Screen
- U.K. Newborn Screening Market Product Outlook (Revenue, USD Million , 2021-2033)
- Instruments
- Reagents
Reasons to subscribe to Newborn Screening Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Newborn Screening Market Outlook databook
- Our clientele includes a mix of Newborn Screening Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.K. Newborn Screening Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.K. Newborn Screening Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
U.K. Newborn Screening Market, 2021-2033 (US$M)
UK newborn screening market statistics, by technology, 2021-2033 (US$M)
